Actuate says elraglusib enters BEACON2 Phase 1/2 trial in relapsed pediatric neuroblastoma

Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc.

ACTU

0.00
  • Actuate Therapeutics’ elraglusib was selected for evaluation in BEACON2, a European Phase 1/2 platform trial in relapsed or refractory pediatric neuroblastoma.
  • The study will test elraglusib with dinutuximab beta and chemotherapy, starting with a dose-confirmation stage focused on safety and dose selection.
  • No BEACON2 results have been presented; data will be generated in the trial as it progresses.
  • Prior early-stage clinical findings were previously reported, including a complete response in a heavily pretreated neuroblastoma patient in a separate Phase 1/2 study.
  • The move expands elraglusib’s pediatric development path, supported by an FDA Rare Pediatric Disease designation for neuroblastoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090745PRIMZONEFULLFEED9733746) on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.